Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Dohner H, Wei AH, Roboz GJ, Montesinos P, et al. Blood 2022;140:1674-1685.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dohner H, Wei AH, Roboz GJ, Montesinos P, et al. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood 2022;140:1674-1685.
PMID: 35960871